secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002318
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 3.02, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics raises $5.0M via warrant exercise; issues new warrants at $0.3006, subject to shareholder approval
--------------------------------------------------------------------------------

- Gross proceeds ~$5.0M from immediate cash exercise of 16.5M existing warrants at reduced exercise price of $0.3006/share.
- New unregistered Series A and Series B warrants each to purchase up to 16.5M shares at $0.3006; exercisable only after stockholder approval.
- Stockholder approval required to increase authorized shares and comply with Nasdaq Rule 5635(d); no voting rights until exercise.
- Maxim Group acted as agent; fees: 3.5% on Jan 2023 warrants and 7.0% on Nov 2023 warrants, plus up to $15,000 expense reimbursement.
- Company intends to use net proceeds for general corporate purposes; closing expected on or about January 9, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465924002318/0001104659-24-002318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465924002318/tm242240d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer